Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | EVP & GENERAL COUNSEL | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,172 |
Ending reported balance
After 2026-10-01 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,300 · Balance 53,472 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Row 2 · 2026-10-01 · Sale · Disposed 880 · Balance 52,592 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-10-01 · Sale · Disposed 1,480 · Balance 51,112 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-10-01 · Sale · Disposed 780 · Balance 50,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-10-01 · Sale · Disposed 1,480 · Balance 48,852 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-10-01 · Sale · Disposed 400 · Balance 48,452 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-10-01 · Sale · Disposed 720 · Balance 47,732 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-10-01 · Sale · Disposed 739 · Balance 46,993 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-10-01 · Sale · Disposed 838 · Balance 46,155 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 10 · 2026-10-01 · Sale · Disposed 823 · Balance 45,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2026-10-01 · Sale · Disposed 160 · Balance 45,172 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 39,240 |
Reported balance
After 2026-10-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-01 · Exercise / conversion · Disposed 8,300 · Balance 39,240 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2024 Filed Dec 20, 2024 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $360.16 | $2,773,232.00 |
DisclosureSEC source: 0001562180-24-008538 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-24-008538 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-24-008216 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,050 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,700 | $374.37 | $2,882,649.00 |
DisclosureSEC source: 0001562180-24-008216 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-24-008216 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001562180-24-007878 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,750 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,700 | $367.36 | $2,828,672.00 |
DisclosureSEC source: 0001562180-24-007878 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 22:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001562180-24-007878 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-026445 · form4-11082024_041103.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,450 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $402.57 | $3,099,789.00 |
DisclosureSEC source: 0001415889-24-026445 · form4-11082024_041103.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001415889-24-026445 · form4-11082024_041103.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 21:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-025430 · form4-10182024_091003.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,150 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F2 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 21:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $372.81 | $2,870,637.00 |
DisclosureSEC source: 0001415889-24-025430 · form4-10182024_091003.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F2 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 21:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001415889-24-025430 · form4-10182024_091003.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| October 03, 2024 Filed Oct 18, 2024 21:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-025430 · form4-10182024_091003.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,850 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · date: This STAP exercise for October 3, 2024 is being reported late due to an administrative error. F2 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| October 03, 2024 Filed Oct 18, 2024 21:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $350.07 | $2,695,539.00 |
DisclosureSEC source: 0001415889-24-025430 · form4-10182024_091003.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · date: This STAP exercise for October 3, 2024 is being reported late due to an administrative error. F2 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| October 03, 2024 Filed Oct 18, 2024 21:19 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001415889-24-025430 · form4-10182024_091003.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This STAP exercise for October 3, 2024 is being reported late due to an administrative error. F2 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 7,700 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-023840 · form4-09232024_040901.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,550 Underlying: Common Stock · 7,700 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 7,700 | $351.33 | $2,705,241.00 |
DisclosureSEC source: 0001415889-24-023840 · form4-09232024_040901.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,700 | $163.30 | $1,257,410.00 |
DisclosureSEC source: 0001415889-24-023840 · form4-09232024_040901.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on June 20, 2024. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 25,000 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-017980 · form4-06242024_040602.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,250 Underlying: Common Stock · 25,000 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 25,000 | $308.98 | $7,724,500.00 |
DisclosureSEC source: 0001415889-24-017980 · form4-06242024_040602.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,710 F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 25,000 | $163.30 | $4,082,500.00 |
DisclosureSEC source: 0001415889-24-017980 · form4-06242024_040602.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · derivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 6,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 206 | $234.09 | $48,222.31 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F6 · price: This transaction was executed in multiple trades at prices ranging from $234.08 to $234.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,041 | $233.64 | $243,221.22 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,916 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $233.00 to $233.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,279 | $232.55 | $762,538.34 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,957 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $231.96 to $232.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,374 | $230.99 | $317,382.18 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,236 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $230.65 to $231.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $228.84 | $22,884.20 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,610 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $228.56 to $229.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2024 Filed Apr 4, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $117.76 | $706,560.00 |
DisclosureSEC source: 0001415889-24-010279 · form4-04042024_040401.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-008956 · form4-03222024_040310.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 6,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,400 | $237.36 | $332,304.14 |
DisclosureSEC source: 0001415889-24-008956 · form4-03222024_040310.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F6 · price: This transaction was executed in multiple trades at prices ranging from $237.22 to $237.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,505 | $236.71 | $829,683.62 |
DisclosureSEC source: 0001415889-24-008956 · form4-03222024_040310.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,110 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $236.20 to $237.195. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 238 | $235.73 | $56,104.17 |
DisclosureSEC source: 0001415889-24-008956 · form4-03222024_040310.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,615 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $235.16 to $236.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 857 | $234.11 | $200,634.07 |
DisclosureSEC source: 0001415889-24-008956 · form4-03222024_040310.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,853 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $233.74 to $234.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $117.76 | $706,560.00 |
DisclosureSEC source: 0001415889-24-008956 · form4-03222024_040310.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · balance_after: Includes 118 shares acquired on March 4, 2024, under the United Therapeutics Corporation Employee Stock Purchase Plan. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 21:52 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-007191 · form4-03072024_090331.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 6,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 21:52 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $238.85 | $71,655.00 |
DisclosureSEC source: 0001415889-24-007191 · form4-03072024_090331.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 21:52 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,700 | $237.76 | $641,949.57 |
DisclosureSEC source: 0001415889-24-007191 · form4-03072024_090331.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,899 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $237.34 to $238.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 21:52 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,000 | $236.90 | $710,704.50 |
DisclosureSEC source: 0001415889-24-007191 · form4-03072024_090331.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $236.34 to $237.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 21:52 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $117.76 | $706,560.00 |
DisclosureSEC source: 0001415889-24-007191 · form4-03072024_090331.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-003924 · form4-02152024_040201.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 6,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,088 | $216.04 | $235,055.65 |
DisclosureSEC source: 0001415889-24-003924 · form4-02152024_040201.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $216.00 to $216.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,362 | $215.43 | $724,289.11 |
DisclosureSEC source: 0001415889-24-003924 · form4-02152024_040201.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,687 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $215.00 to $215.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,550 | $214.54 | $332,540.10 |
DisclosureSEC source: 0001415889-24-003924 · form4-02152024_040201.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,049 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $213.99 to $214.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $117.76 | $706,560.00 |
DisclosureSEC source: 0001415889-24-003924 · form4-02152024_040201.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-002296 · form4-02022024_040201.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 6,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $216.37 | $86,546.00 |
DisclosureSEC source: 0001415889-24-002296 · form4-02022024_040201.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $216.23 to $216.535. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,799 | $215.72 | $603,787.96 |
DisclosureSEC source: 0001415889-24-002296 · form4-02022024_040201.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,999 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $215.16 to $216.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,601 | $214.53 | $343,455.49 |
DisclosureSEC source: 0001415889-24-002296 · form4-02022024_040201.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,798 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on March 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $214.085 to $215.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.